By chromatin immunoprecipitation assay (ChIP), we found that TSA treatment did not increase the binding of acetyl-histone H3 to the MIG-6 promoter in the lung cancer lines or in the melanoma lines (Figure 5), indicating that the MIG-6 promoter was not directly affected by histone deacetylation either. The gene discussed is ERRFI1; the disease is melanoma.